Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- IMCR
- Price
- 32.38
- Stock movement up
- +0.10 (0.31%)
- Company name
- Immunocore Holdings Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.64B
- Ent value
- 1.84B
- Price/Sales
- 4.31
- Price/Book
- 4.13
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 180.51%
- 1 year return (CAGR)
- 8.88%
- 3 year return (CAGR)
- -19.30%
- 5 year return (CAGR)
- -8.71%
- 10 year return (CAGR)
- -
Last updated: 2026-03-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMCR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 204.73 |
| Price to FCF | 555.01 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.31 |
| Price to Book | 4.13 |
| EV to Sales | 4.86 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.53M |
| EPS (TTM) | -0.53 |
| FCF per share (TTM) | -0.30 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 372.97M |
| Gross profit (TTM) | 367.96M |
| Operating income (TTM) | -40.25M |
| Net income (TTM) | -26.77M |
| EPS (TTM) | -0.53 |
| EPS (1y forward) | -1.01 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.66% |
| Operating margin (TTM) | -10.79% |
| Profit margin (TTM) | -7.18% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 467.71M |
| Net receivables | 73.98M |
| Total current assets | 996.74M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 111.05M |
| Total assets | 1.07B |
| Accounts payable | 24.36M |
| Short/Current long term debt | 43.56M |
| Total current liabilities | 246.70M |
| Total liabilities | 686.24M |
| Shareholder's equity | 381.03M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -10.71M |
| Capital expenditures (TTM) | 4.34M |
| Free cash flow (TTM) | -15.05M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -7.03% |
| Return on Assets | -2.51% |
| Return on Invested Capital | -3.45% |
| Cash Return on Invested Capital | -1.94% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 32.29 |
| Daily high | 32.98 |
| Daily low | 31.89 |
| Daily Volume | 207K |
| All-time high | 75.36 |
| 1y analyst estimate | 65.01 |
| Beta | 0.82 |
| EPS (TTM) | -0.53 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| IMCR | S&P500 | |
| Current price drop from All-time high | -57.03% | -1.82% |
| Highest price drop | -67.45% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -35.16% | -10.84% |
| Avg time to new high | 67 days | 12 days |
| Max time to new high | 508 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.64B
Marketcap category
Small-cap
Description
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Employees
524
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page